Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population

Mukker, Jatinder Kaur; Singh, Ravinderjit; Derendorf, Hartmut

doi:10.1007/978-3-319-43099-7_10

Cited by 7 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies show that older people are more susceptible to DDIs because they are more sensitive to pharmacokinetic effects, and often due to concomitant illnesses, these patients are taking more than two drugs at a time. [16]…”

Section: Discussionmentioning

confidence: 99%

Impact of clinical pharmacist's interventions on potential drug–Drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran

et al. 2019

View full text Add to dashboard Cite

Objective:The main objective of this study aimed to assess drug–drug interactions (DDIs) in the cardiac care unit (CCU) and cardiac surgery units and the role of a clinical pharmacist in detecting and preventing the expected DDIs.Methods:This cross-sectional study was conducted in the CCU Units of Nemazee and Shahid Faghihi Hospitals, two referral hospitals in Shiraz, South of Iran, from August to February 2016. Patients older than 18 years, who were admitted and had received >24 h of inpatient services in these wards with two or more medication orders, were included in this study. All medication orders were evaluated by a pharmacist and DDIs were examined based on the Lexi-Interact™ software. In cases with serious DDIs (D or X), the physicians and nurses were informed, and intervention was conducted by a clinical pharmacist.Findings:A total of 3706 medical orders were evaluated. 6478 DDIs were detected, of which, 446 (6.88%) belonged to Classes D and X, and a total of 43.43% of all hospitalizations had at least one DDI. Factors with the most considerable influence on DDIs included an increased number of prescribed medications and patients underlying disease. The physicians accepted 62% of the interventions. The most frequent drugs responsible for interactions of Classes C, D, and X were aspirin, warfarin, and clopidogrel, respectively.Conclusion:This study shows that a significant number of clinical DDIs exist in hospitalized patients, especially among consumers of warfarin and aspirin. The role of a clinical pharmacist in preventing such interactions and safer pharmacotherapy management for hospitalized patients is essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of clinical pharmacist's interventions on potential drug–Drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran

et al. 2019

View full text Add to dashboard Cite

show abstract

Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals

Neverette,

Dumond,

McMahon

et al. 2024

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The mainstay of antiretroviral therapy (ART) has been combination oral therapy. While oral ART is highly effective, nonadherence remains a chief concern. Addressing this concern in recent years is the emergence of long‐acting antiretrovirals for the treatment and prevention of HIV‐1 infection. The most recently approved long‐acting antiretroviral is the first‐in‐class capsid inhibitor lenacapavir (LEN) for heavily treatment‐experienced adults with multidrug‐resistant HIV‐1 infection. Due to its biannual subcutaneous dosing scheme to inhibit the HIV‐1 capsid, LEN exhibits unique pharmacokinetics and reinforces an evolving era of ART. In this review, we evaluate published and accepted research articles, conference proceedings, and clinical trial records to provide a comprehensive overview of LEN for treatment and preliminary data for the prevention of HIV‐1 infection. These data include clinical trials outcomes, in vitro and in vivo resistance profiles, and preclinical data supporting downstream indications. We also discuss the unique clinical pharmacology of LEN with the goal of serving as a resource toward subsequent physiologically based, population‐based, and other miscellaneous pharmacometric‐focused analyses. Given the dynamic nature of the HIV treatment and prevention research fields, we also discuss ongoing studies related to LEN for treatment‐naïve adults and for prevention. Lastly, we discuss important pharmacologic gaps in special populations, drug–drug interactions, and at the sites of action germane to HIV treatment and prevention. The information discussed in this review will provide knowledge and understanding of the unique pharmacologic properties of LEN to assist clinicians and researchers as they navigate the dynamic HIV research landscape.

show abstract

Medication Use and Falls in People with Cognitive Impairment. Assessment and Management Strategies

Huang

Mallet

2019

Falls and Cognition in Older Persons

View full text Add to dashboard Cite

Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population

Cited by 7 publications

References 60 publications

Impact of clinical pharmacist's interventions on potential drug–Drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran

Impact of clinical pharmacist's interventions on potential drug–Drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran

Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals

Medication Use and Falls in People with Cognitive Impairment. Assessment and Management Strategies

Contact Info

Product

Resources

About